sunshine biopharma inc (sbfm) is a pharmaceuticals company based out of 469 jean-talon west, 3rd floor, montreal, québec, canada.
Company profile
Ticker
SBFM
Exchange
Website
CEO
Steve N. Slilaty
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
mountain state business solutions,inc, Mountain West Business Solutions, Inc, mountain west business solutions,inc
SEC CIK
Corporate docs
Subsidiaries
Sunshine Biopharma Canada Inc. • Nora Pharma Inc. ...
IRS number
205566275
SBFM stock data
Latest filings (excl ownership)
8-K
Results of Operations and Financial Condition
22 May 24
10-Q
2024 Q1
Quarterly report
20 May 24
NT 10-Q
Notice of late quarterly filing
15 May 24
8-K
Changes in Registrant's Certifying Accountant
8 May 24
8-K
Changes in Registrant's Certifying Accountant
6 May 24
8-K
Amendments to Articles of Incorporation or Bylaws
23 Apr 24
8-K
Sales Grew at an Average Rate of 14% Per Quarter During the Year
1 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
DEF 14C
Information statement
15 Mar 24
8-K
Entry into a Material Definitive Agreement
6 Mar 24
Latest ownership filings
4
Steve N. Slilaty
5 Mar 24
SC 13G
L1 Capital Global Opportunities Master Fund, Ltd.
23 Feb 24
SC 13G
Altium Capital Management LP
21 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Steve N. Slilaty
12 Feb 24
3
Marc Beaudoin
9 Feb 24
4
Camille Sebaaly
2 Dec 22
SC 13G
Chamoun Malek
2 Nov 22
3
Malek Chamoun
26 Oct 22
4
Camille Sebaaly
6 Jun 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.43 mm | 17.43 mm | 17.43 mm | 17.43 mm | 17.43 mm | 17.43 mm |
Cash burn (monthly) | (no burn) | 155.00 k | 450.20 k | 358.91 k | 1.06 mm | 842.51 k |
Cash used (since last report) | n/a | 270.52 k | 785.73 k | 626.41 k | 1.85 mm | 1.47 mm |
Cash remaining | n/a | 17.16 mm | 16.65 mm | 16.81 mm | 15.58 mm | 15.96 mm |
Runway (months of cash) | n/a | 110.7 | 37.0 | 46.8 | 14.7 | 18.9 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 8 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 1.25 bn |
Total shares | 41.75 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Beathard Robert King 3rd | 39.23 mm | $4.75 mm |
Armistice Capital | 2.19 mm | $1.08 bn |
Bridgeway Capital Management | 286.10 k | $141.48 mm |
Geode Capital Management | 20.18 k | $9.98 mm |
Advisor | 11.98 k | $5.92 mm |
National Bank of Canada | 6.04 k | $2.90 mm |
New England Capital Financial Advisors | 500.00 | $248.00 k |
MS Morgan Stanley | 26.00 | $13.00 k |
UBS UBS Group AG - Registered Shares | 1.00 | $0.00 |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Slilaty Steve N. | Series B Preferred Stock | Buy | Acquire P | No | No | 0.1 | 100,000 | 10.00 k | 130,000 |
8 Feb 24 | Slilaty Steve N. | Series B Preferred Stock | Buy | Acquire P | No | No | 0.1 | 20,000 | 2.00 k | 30,000 |
30 Nov 22 | Sebaaly Camille | Common Stock | Buy | Acquire P | No | No | 0.7635 | 30,000 | 22.91 k | 174,465 |
News
Sunshine Biopharma Q1 EPS $(2.00) Misses $(1.04) Estimate, Sales $7.54M Beat $7.00M Estimate
21 May 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
14 May 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
6 May 24
12 Health Care Stocks Moving In Friday's Intraday Session
26 Apr 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
25 Apr 24
Press releases
Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%
21 May 24
Sunshine Biopharma Announces Reverse Stock Split
12 Apr 24
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023
1 Apr 24
Thinking about buying stock in Mediwound, AeroVironment, Airship AI, Lyell Immunopharma, or Sunshine Biopharma?
6 Mar 24